Precipio, Inc.

Precipio, Inc. (PRPO) is a publicly traded US company. Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

The company reports trailing twelve-month revenue of $6.71M and net loss of $1.44M.

Key metrics include a return on equity of -10.0%, a debt-to-equity ratio of 0.46.

Investors tracking PRPO can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.